GlassScriptPhysician profile
Madhavi E Ryali
NPI 1356453823
$2,792.83
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $284 · 2021: $544 · 2022: $602 · 2023: $385 · 2024: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394 · Consulting Fee: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.00 |
| Consulting Fee | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $739.64 | 2019-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $412.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $185.82 | 2019-2023 | Farxiga |
| Aurinia Pharma U.S., INC. | $167.61 | 2021 | |
| Glaxosmithkline, LLC. | $140.00 | 2023 | Benlysta |
| Nxstage Medical, INC. | $135.19 | 2022-2023 | Liberty Select Cycler, Nxstage System One |
| Abbott Laboratories | $131.32 | 2019 | |
| Mallinckrodt Enterprises LLC | $127.54 | 2019 | |
| Genentech, INC. | $119.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $114.73 | 2019 | |
| Akebia Therapeutics INC | $97.02 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $92.03 | 2020-2024 | Jynarque |
| Amgen INC. | $77.40 | 2019-2024 | Tavneos |
| Travere Therapeutics, INC. | $55.88 | 2023 | |
| Horizon Therapeutics Plc | $50.30 | 2023 | Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $42.45 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $42.37 | 2024 | |
| Shire North American Group INC | $20.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.46 | 2022 | |
| Ardelyx, INC. | $20.45 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Ryali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.